At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 752 enrolled
Drug / intervention
Cariprazinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Long-term Safety, Tolerability, and Pharmacokinetics of Cariprazine in Patients With Schizophrenia
In Brief
A Phase 3 clinical trial evaluating Cariprazine for Schizophrenia. Completed, enrolled 752 participants across 86 sites in 6 countries.
Detailed Summary
The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesColombia, India, Romania, Russia, Ukraine, United States
CollaboratorsGedeon Richter Ltd.
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2010
Enrollment StartMay 2010
Primary CompletionJan 2013
TodayJul 2026
First PostedApr 15, 2010
Enrollment StartMay 31, 2010
Primary CompletionJan 31, 2013
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 16.2 years ago
Interventions
Cariprazinedrug
Cariprazine was supplied in capsules.